title: Cell death induced by novel procaspase-3 activators can be reduced by growth factors.
abstract: Caspase-3 is known as the key executioner caspase, activated in both the intrinsic and extrinsic apoptotic pathway, and an effector far downstream in the apoptotic cascade. Procaspase-activating compound-1 (PAC-1) and 1541 were launched as direct activators of procaspase-3 to caspase-3, and anticipated to be promising therapeutic agents for the treatment of cancer. PAC-1 has recently been evaluated in a phase I preclinical trial. However, little is known about the effect of these substances in cells. Activation of caspase-3 in whole cells may be more complicated than thought, as it is likely that this key protease is tightly regulated both in development and apoptosis. In this study, we investigated the effect of epidermal growth factor (EGF) on PAC-1-induced caspase-3 activity and cell death. We show that EGF can block caspase-3 activity generated by PAC-1, and protect both PC12 cells and primary cerebellar granule neurons against PAC-1-induced death. Similar results were obtained with 1541. Both substances reduced cellular p-ERK levels. Crosstalk between caspase-3 and growth factor signaling pathways may present a challenge for the use of such caspase-3-activating substances in cancer therapy, since aberrant growth factor signaling is frequently seen in malignant cells. This study adds important knowledge about cellular effects of procaspase-3 activators like PAC-1 and 1541. Effects mediated by these substances may also contribute to the understanding of caspase signaling in cells.
authors: Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway.
authors: Karen A
authors: KA
authors: Boldingh Debernard
authors: Gulzeb
authors: G
authors: Aziz
authors: Annine Thomassen
authors: AT
authors: Gjesvik
authors: Ragnhild E
authors: RE
authors: Paulsen
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3 / Q000096:biosynthesis*; D061945:Caspase Inhibitors; D002642:Chick Embryo; D004789:Enzyme Activation / Q000187:drug effects; D020536:Enzyme Activators / Q000494:pharmacology*; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D006835:Hydrazones / Q000494:pharmacology*; D016716:PC12 Cells; D010879:Piperazines / Q000494:pharmacology*; D051381:Rats
chemical_list: C514579:(4-benzylpiperazin-1-yl)acetic acid (3-allyl-2-hydroxybenzylidene)hydrazine; D061945:Caspase Inhibitors; D020536:Enzyme Activators; D006835:Hydrazones; D010879:Piperazines; D004815:Epidermal Growth Factor; D053148:Caspase 3